These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 31734605)

  • 21. Potentially functional genetic variants in KDR gene as prognostic markers in patients with resected colorectal cancer.
    Dong G; Guo X; Fu X; Wan S; Zhou F; Myers RE; Bao G; Burkart A; Yang H; Xing J
    Cancer Sci; 2012 Mar; 103(3):561-8. PubMed ID: 22182247
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Germline variation in colorectal risk Loci does not influence treatment effect or survival in metastatic colorectal cancer.
    Sanoff HK; Renfro LA; Poonnen P; Ambadwar P; Sargent DJ; Goldberg RM; McLeod H
    PLoS One; 2014; 9(4):e94727. PubMed ID: 24727911
    [TBL] [Abstract][Full Text] [Related]  

  • 23.
    Deligonul A; Aksoy S; Tezcan G; Tunca B; Kanat O; Cubukcu E; Yilmazlar T; Ozturk E; Egeli U; Cecener G; Alemdar A; Evrensel T
    Genet Test Mol Biomarkers; 2021 Apr; 25(4):276-283. PubMed ID: 33877893
    [No Abstract]   [Full Text] [Related]  

  • 24. CDH1 germline variants are enriched in patients with colorectal cancer, gastric cancer, and breast cancer.
    Adib E; El Zarif T; Nassar AH; Akl EW; Abou Alaiwi S; Mouhieddine TH; Esplin ED; Hatchell K; Nielsen SM; Rana HQ; Choueiri TK; Kwiatkowski DJ; Sonpavde G
    Br J Cancer; 2022 Mar; 126(5):797-803. PubMed ID: 34949788
    [TBL] [Abstract][Full Text] [Related]  

  • 25. E-cadherin (CDH1) gene promoter polymorphism and the risk of colorectal cancer : a meta-analysis.
    Wang Y; Yang H; Li L; Wang H; Zhang C; Xia X
    Int J Colorectal Dis; 2012 Feb; 27(2):151-8. PubMed ID: 21997289
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Genome-wide association study identifies tumor anatomical site-specific risk variants for colorectal cancer survival.
    Labadie JD; Savas S; Harrison TA; Banbury B; Huang Y; Buchanan DD; Campbell PT; Gallinger SJ; Giles GG; Gunter MJ; Hoffmeister M; Hsu L; Jenkins MA; Lin Y; Ogino S; Phipps AI; Slattery ML; Steinfelder RS; Sun W; Van Guelpen B; Hua X; Figuieredo JC; Pai RK; Nassir R; Qi L; Chan AT; Peters U; Newcomb PA
    Sci Rep; 2022 Jan; 12(1):127. PubMed ID: 34996992
    [TBL] [Abstract][Full Text] [Related]  

  • 27. E-cadherin (CDH1) gene -160C/A polymorphism and the risk of colorectal cancer: A meta-analysis involving 17,291 subjects.
    Ye CC; Wang J
    J Gene Med; 2021 Oct; 23(10):e3370. PubMed ID: 34097324
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Short article: Influence of regulatory NLRC5 variants on colorectal cancer survival and 5-fluorouracil-based chemotherapy.
    Catalano C; da Silva Filho MI; Jiraskova K; Vymetalkova V; Levy M; Liska V; Vycital O; Naccarati A; Vodickova L; Hemminki K; Vodicka P; Weber ANR; Försti A
    Eur J Gastroenterol Hepatol; 2018 Aug; 30(8):838-842. PubMed ID: 29762254
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Association of clinicopathological features with E-cadherin (CDH1) gene-160 C>A promoter polymorphism in Turkish colorectal cancer patients.
    Bahadir A; Eral G; Budak M; Shimamoto F; Korpinar MA; Erdamar S; Tuncel H
    J Cancer Res Ther; 2019; 15(1):26-31. PubMed ID: 30880750
    [TBL] [Abstract][Full Text] [Related]  

  • 30. AGXT and ERCC2 polymorphisms are associated with clinical outcome in metastatic colorectal cancer patients treated with 5-FU/oxaliplatin.
    Kjersem JB; Thomsen M; Guren T; Hamfjord J; Carlsson G; Gustavsson B; Ikdahl T; Indrebø G; Pfeiffer P; Lingjærde O; Tveit KM; Wettergren Y; Kure EH
    Pharmacogenomics J; 2016 Jun; 16(3):272-9. PubMed ID: 26261061
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Angiogenic and Antiangiogenic VEGFA Splice Variants in Colorectal Cancer: Prospective Retrospective Cohort Study in Patients Treated With Irinotecan-Based Chemotherapy and Bevacizumab.
    Pentheroudakis G; Mavroeidis L; Papadopoulou K; Koliou GA; Bamia C; Chatzopoulos K; Samantas E; Mauri D; Efstratiou I; Pectasides D; Makatsoris T; Bafaloukos D; Papakostas P; Papatsibas G; Bombolaki I; Chrisafi S; Kourea HP; Petraki K; Kafiri G; Fountzilas G; Kotoula V
    Clin Colorectal Cancer; 2019 Dec; 18(4):e370-e384. PubMed ID: 31402291
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A polymorphism within the R-spondin 2 gene predicts outcome in metastatic colorectal cancer patients treated with FOLFIRI/bevacizumab: data from FIRE-3 and TRIBE trials.
    Berger MD; Ning Y; Stintzing S; Heinemann V; Cao S; Zhang W; Yang D; Miyamoto Y; Suenaga M; Schirripa M; Hanna DL; Soni S; Puccini A; Tokunaga R; Naseem M; Battaglin F; Cremolini C; Falcone A; Loupakis F; Lenz HJ
    Eur J Cancer; 2020 May; 131():89-97. PubMed ID: 32305727
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Predictive and prognostic implications of 4E-BP1, Beclin-1, and LC3 for cetuximab treatment combined with chemotherapy in advanced colorectal cancer with wild-type KRAS: Analysis from real-world data.
    Guo GF; Wang YX; Zhang YJ; Chen XX; Lu JB; Wang HH; Jiang C; Qiu HQ; Xia LP
    World J Gastroenterol; 2019 Apr; 25(15):1840-1853. PubMed ID: 31057298
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Expression quantitative trait loci in ABC transporters are associated with survival in 5-FU treated colorectal cancer patients.
    Vymetalkova V; Rosa F; Susova S; Bendova P; Levy M; Buchler T; Kral J; Bartu L; Vodickova L; Hughes DJ; Soucek P; Naccarati A; Kumar R; Vodicka P; Pardini B
    Mutagenesis; 2020 Jul; 35(3):273-281. PubMed ID: 31922572
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Identification of polymorphisms in ultraconserved elements associated with clinical outcomes in locally advanced colorectal adenocarcinoma.
    Lin M; Eng C; Hawk ET; Huang M; Lin J; Gu J; Ellis LM; Wu X
    Cancer; 2012 Dec; 118(24):6188-98. PubMed ID: 22673945
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Role of enterocyte-specific gene polymorphisms in response to adjuvant treatment for stage III colorectal cancer.
    Suenaga M; Cao S; Zhang W; Matsusaka S; Okazaki S; Berger MD; Miyamoto Y; Schirripa M; Barzi A; Yamamoto N; Yamaguchi T; Lenz HJ
    Pharmacogenet Genomics; 2021 Jan; 31(1):10-16. PubMed ID: 32732498
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Genome-wide association studies of survival in 1520 cancer patients treated with bevacizumab-containing regimens.
    Quintanilha JCF; Wang J; Sibley AB; Xu W; Espin-Garcia O; Jiang C; Etheridge AS; Ratain MJ; Lenz HJ; Bertagnolli M; Kindler HL; Dickler MN; Venook A; Liu G; Owzar K; Lin D; Innocenti F
    Int J Cancer; 2022 Jan; 150(2):279-289. PubMed ID: 34528705
    [TBL] [Abstract][Full Text] [Related]  

  • 38. AMPK variant, a candidate of novel predictor for chemotherapy in metastatic colorectal cancer: A meta-analysis using TRIBE, MAVERICC and FIRE3.
    Tokunaga R; Cao S; Naseem M; Battaglin F; Lo JH; Arai H; Loupakis F; Stintzing S; Puccini A; Berger MD; Soni S; Zhang W; Mancao C; Salhia B; Mumenthaler SM; Weisenberger DJ; Liang G; Cremolini C; Heinemann V; Falcone A; Millstein J; Lenz HJ
    Int J Cancer; 2019 Oct; 145(8):2082-2090. PubMed ID: 30856283
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Randomised phase II study of panitumumab plus irinotecan versus cetuximab plus irinotecan in patients with KRAS wild-type metastatic colorectal cancer refractory to fluoropyrimidine, irinotecan and oxaliplatin (WJOG 6510G).
    Sakai D; Taniguchi H; Sugimoto N; Tamura T; Nishina T; Hara H; Esaki T; Denda T; Sakamoto T; Okuda H; Satoh T; Tsushima T; Makiyama A; Tsuda T; Hosokawa A; Kuramochi H; Tokunaga S; Moriwaki T; Yasui H; Ishida H; Tsuji A; Otsu S; Shimokawa H; Baba E; Sato M; Matsumoto S; Ozaki Y; Shinozaki K; Tamagawa H; Goto M; Kadowaki S; Fujii H; Koh Y; Yamazaki K; Hironaka S; Kishimoto J; Boku N; Hyodo I; Muro K
    Eur J Cancer; 2020 Aug; 135():11-21. PubMed ID: 32526634
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Systematic meta-analyses, field synopsis and global assessment of the evidence of genetic association studies in colorectal cancer.
    Montazeri Z; Li X; Nyiraneza C; Ma X; Timofeeva M; Svinti V; Meng X; He Y; Bo Y; Morgan S; Castellví-Bel S; Ruiz-Ponte C; Fernández-Rozadilla C; Carracedo Á; Castells A; Bishop T; Buchanan D; Jenkins MA; Keku TO; Lindblom A; van Duijnhoven FJB; Wu A; Farrington SM; Dunlop MG; Campbell H; Theodoratou E; Zheng W; Little J
    Gut; 2020 Aug; 69(8):1460-1471. PubMed ID: 31818908
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.